Literature DB >> 35833999

Crohn's disease active inflammation assessment with iodine density from dual-energy CT enterography: comparison with endoscopy and conventional interpretation.

Bari Dane1,2, Amelia Kernizan3,4, Thomas O'Donnell5,4, Robert Petrocelli3,4, Wendy Rabbenou4,6, Sumona Bhattacharya4,6, Shannon Chang4,6, Alec Megibow3,4.   

Abstract

PURPOSE: To compare terminal ileum (TI) mucosal iodine density obtained at dual-energy CT enterography (DECTE) with conventional CT interpretation and endoscopy in patients with Crohn's disease (CD).
MATERIALS AND METHODS: Twenty-three CD patients (14 men; mean[SD] age:48.1[16.7] years) with endoscopy within 30 days of DECTE were retrospectively identified. An inflammatory bowel disease gastroenterologist reviewed endoscopic images. Two radiologists qualitatively assessed the presence of active TI inflammation. Mean iodine density normalized to the aorta (I%), mean absolute iodine density (I), and iodine density standard deviation (ISD) from the distal 2 cm ileum (TI) mucosa obtained using semiautomatic prototype software were compared with endoscopic assessment using Mann Whitney tests. The optimal threshold I% and I were determined from receiver operating curves (ROC). Sensitivity and specificity of conventional interpretation and determined iodine thresholds were compared using McNemar's test. Inter-reader agreement was assessed using kappa. A p < 0.05 indicated statistical significance.
RESULTS: Twelve (52.1%) patients had endoscopic active inflammation. I% was 37.9[13.3]% for patients with and 21.7[7.5]% for patients without endoscopic active inflammation (p = 0.001). The optimal ROC threshold 24.6% had 100% sensitivity and 81.8% specificity (AUC = 0.909, 95% CI 0.777-1). I was 2.44[0.73]mg/mL for patients with and 1.77[1.00]mg/mL for patients without active endoscopic inflammation (p = 0.0455). The optimal ROC threshold 1.78 mg/mL I had 91.7% sensitivity and 63.6% specificity (AUC = 0.75, 95% CI 0.532-0.968). ISD was similar for patients with and without endoscopic active inflammation (0.82[0.33]mg/mL and 0.77[0.28]mg/mL, respectively, p = 0.37). Conventional interpretation sensitivity and specificity (R1/R2) were 83.3%/91.7% and 72.7%/54.5%, respectively (all p > 0.05) with moderate inter-reader agreement (Κ = 0.542[95% CI 0.0202-0.088]).
CONCLUSION: Mean normalized iodine density is highly sensitive and specific for endoscopic active inflammation. DECTE could be considered as a surrogate to endoscopy in CD patients. Despite trends towards improved sensitivity and specificity compared with conventional interpretation, future larger studies are needed.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CT enterography; Crohn disease; Dual-energy CT enterography; Inflammatory bowel disease; Iodine density

Mesh:

Substances:

Year:  2022        PMID: 35833999     DOI: 10.1007/s00261-022-03605-2

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  24 in total

1.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy.

Authors:  Sunil Samuel; David H Bruining; Edward V Loftus; Brenda Becker; Joel G Fletcher; Jayawant N Mandrekar; Alan R Zinsmeister; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-04-10       Impact factor: 11.382

3.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

Authors:  Dan Turner; Amanda Ricciuto; Ayanna Lewis; Ferdinando D'Amico; Jasbir Dhaliwal; Anne M Griffiths; Dominik Bettenworth; William J Sandborn; Bruce E Sands; Walter Reinisch; Jürgen Schölmerich; Willem Bemelman; Silvio Danese; Jean Yves Mary; David Rubin; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Iris Dotan; Maria T Abreu; Axel Dignass
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

Review 4.  Clinical trials in luminal Crohn's disease: a historical perspective.

Authors:  Pieter Hindryckx; Filip Baert; Ailsa Hart; Alessandro Armuzzi; Julian Panès; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2014-05-17       Impact factor: 9.071

Review 5.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

6.  Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease.

Authors:  Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2011-09-16       Impact factor: 5.325

7.  Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection.

Authors:  Miguel Regueiro; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Antonia R Sepulveda; Marilyn Pesci; Sandra El-Hachem; Janet Harrison; David Binion
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

8.  Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence.

Authors:  David H Bruining; Hassan A Siddiki; Joel G Fletcher; William J Sandborn; Jeff L Fidler; James E Huprich; Jayawant N Mandrekar; William S Harmsen; Paul E Evans; William A Faubion; Karen A Hanson; Steven B Ingle; Darrell S Pardi; Kenneth W Schroeder; William J Tremaine; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2011-02-17       Impact factor: 5.325

9.  Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.

Authors:  Laurent Peyrin-Biroulet; Walter Reinisch; Jean-Frederic Colombel; Gerassimos J Mantzaris; Asher Kornbluth; Robert Diamond; Paul Rutgeerts; Linda K Tang; Freddy J Cornillie; William J Sandborn
Journal:  Gut       Date:  2013-08-23       Impact factor: 23.059

Review 10.  Targeting mucosal healing in Crohn's disease: what the clinician needs to know.

Authors:  Entcho Klenske; Christian Bojarski; Maximilian Waldner; Timo Rath; Markus F Neurath; Raja Atreya
Journal:  Therap Adv Gastroenterol       Date:  2019-06-14       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.